Loading..

Chimerix, Inc. (CMRX) Report Analysis

Corporate Events

Neutral

Chimerix, Inc. Enters into A Supply Agreement w...

2022-06-28 10:06:00

Chimerix, Inc. entered into a Supply Agreement with a third party outside of North America (the “Purchaser”), pursuant to which the Company is...

Neutral

Chimerix Announces TEMBEXA Procurement Agreemen...

2022-06-24 14:06:00

Chimerix announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA(R) (brincidofov...

Neutral

Chimerix Announces $9.3 Million International T...

2022-06-23 13:15:00

Chimerix announced a $9.3 million agreement to procure TEMBEXA(R) (brincidofovir) with a third party outside of North America, with authorizat...

Negative

Chimerix, Inc.(NasdaqGM:CMRX) dropped from S&P ...

2022-06-11 00:00:00

Chimerix, Inc.(NasdaqGM:CMRX) dropped from S&P Biotechnology Select Industry Index

Neutral

Chimerix, Inc. Presents at 2022 Jefferies Globa...

2022-06-01 20:30:00

Chimerix, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 03:30 PM. Venue: Marriott Marquis, New York City, New York...

Neutral

Chimerix, Inc. Presents at H.C. Wainwright Glob...

2022-05-19 10:18:00

Chimerix, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 44...

Positive

Emergent BioSolutions Inc. (NYSE:EBS) entered i...

2022-05-16 00:00:00

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® fro...

Neutral

Maxim Group LLC, Exploring New Targets for Ped...

2022-05-12 20:15:00

Maxim Group LLC, Exploring New Targets for Pediatric Brain Cancer, May 19, 2022.

Neutral

Chimerix, Inc. Presents at Exploring New Target...

2022-05-12 20:15:00

Chimerix, Inc. Presents at Exploring New Targets for Pediatric Brain Cancer, May-19-2022 09:00 AM. Speakers: Joshua E. Allen, Chief Technology...

Neutral

Chimerix, Inc. to Report Q1, 2022 Results on Ma...

2022-05-09 11:00:00

Chimerix, Inc. announced that they will report Q1, 2022 results on May 16, 2022

Neutral

Chimerix, Inc., Q1 2022 Earnings Call, May 16, 2022

2022-05-09 11:00:00

Chimerix, Inc., Q1 2022 Earnings Call, May 16, 2022

Neutral

Chimerix, Inc., Annual General Meeting, Jun 23, 2022

2022-04-28 17:08:00

Chimerix, Inc., Annual General Meeting, Jun 23, 2022, at 08:00 US Eastern Standard Time. Location: The Umstead Hotel and Spa, located at 100 W...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Positive

Chimerix, Inc. Enters into Loan and Security Agreement

2022-02-01 11:14:00

On January 31, 2022, Chimerix, Inc. entered into a Loan and Security Agreement,by and between the Company, as borrower, and Silicon Valley Ban...

Neutral

Biomedical Advanced Research and Development Au...

2021-12-23 11:42:00

On December 22, 2021, the Biomedical Advanced Research and Development Authority issued a Request for Proposal to Chimerix, Inc. which confirm...

Positive

Chimerix, Inc.(NasdaqGM:CMRX) added to NASDAQ B...

2021-12-20 00:00:00

Chimerix, Inc. has been added to NASDAQ Biotechnology Index.

Positive

Chimerix Announces Positive ONC201 Data in Recu...

2021-11-19 12:00:00

Chimerix announced the presentation of positive data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mu...

Neutral

Chimerix, Inc. - Special Call

2021-11-19 12:00:00

To discuss presentation of positive data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mutant diffuse...

Neutral

Chimerix, Inc. Presents at 12th Annual Jefferie...

2021-11-12 13:09:00

Chimerix, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Positive

Chimerix to Seek Acquisition

2021-11-04 16:15:00

Chimerix, Inc. (NasdaqGM:CMRX) will look for acquisition. The company said, "In addition to our transactions with Cantex Pharmaceuticals, Inc....

Positive

Chimerix Announces Positive Topline Results for...

2021-11-04 11:00:00

Chimerix reported positive topline data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mutant glioma. ...

Neutral

Chimerix, Inc. to Report Q3, 2021 Results on No...

2021-10-28 11:00:00

Chimerix, Inc. announced that they will report Q3, 2021 results on Nov 04, 2021

Neutral

Chimerix, Inc., Q3 2021 Earnings Call, Nov 04, 2021

2021-10-28 11:00:00

Chimerix, Inc., Q3 2021 Earnings Call, Nov 04, 2021

Neutral

Chimerix, Inc. Presents at 30th Annual Credit S...

2021-10-01 10:34:00

Chimerix, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 09:40 AM. Venue: Rancho Palos Verdes, California, Unit...

Neutral

Chimerix, Inc. Presents at H.C. Wainwright 23rd...

2021-09-09 14:24:00

Chimerix, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel,...

Neutral

Chimerix, Inc. Presents at 12th Annual Wedbush ...

2021-08-02 10:14:00

Chimerix, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-10-2021 10:55 AM. Speakers: Michael A. Sherman, CEO,...

Neutral

Chimerix, Inc., Q2 2021 Earnings Call, Aug 05, 2021

2021-07-29 11:00:00

Chimerix, Inc., Q2 2021 Earnings Call, Aug 05, 2021

Neutral

Chimerix, Inc. to Report Q2, 2021 Results on Au...

2021-07-29 11:00:00

Chimerix, Inc. announced that they will report Q2, 2021 results on Aug 05, 2021

Neutral

Wedbush Securities Inc., 12th Annual Wedbush Pa...

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Neutral

Chimerix, Inc. Enters into A Supply Agreement with A Third Party Outside of North America

2022-06-28 10:06:00

Chimerix, Inc. entered into a Supply Agreement with a third party outside of North America (the “Purchaser”), pursuant to which the Company is responsible for supplying to the Purchaser, and the Purchaser is responsible for purchasing from the Company, TEMBEXA (brincidofovir) treatment courses for use outside of the United States. TEMBEXA is a medical countermeasure for smallpox approved by the U.S. Food and Drug Administration in June 2021. Under the terms of the Supply Agreement, the Purchaser has agreed to pay the Company an aggregate purchase price of approximately $9.3 million, to be made in two equal installments. The first installment is payable upon execution of the Supply Agreement, and the second installment will be payable upon delivery of the treatment courses, as described in the Supply Agreement. Unless earlier terminated, the term of the Supply Agreement continues until the delivery of the TEMBEXA treatment courses under the Supply Agreement is complete. The Company and the Purchaser each have normal and customary termination rights, including termination for material breach that is not cured within a specific timeframe. Additionally, the Company and the Purchaser each have the right to terminate the Supply Agreement, subject to certain limitations. Additionally, on June 23, 2022, the Public Health Agency of Canada (“PHAC”) awarded a Contract (the “PHAC Contract”) to the Company, pursuant to which PHAC will purchase up to approximately CAD $33.0 million (USD $25.3 million) of TEMBEXA treatment courses for use in Canada. The term of the PHAC Contract continues until the deliveries of the TEMBEXA treatment courses under the PHAC Contract are complete. References to “CAD” are to the Canadian dollar. The U.S. dollar equivalents listed above in this paragraph were calculated based on an exchange rate of CAD 1.00 to USD 0.7695 as of the close of business on June 23, 2022.

Neutral

Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada

2022-06-24 14:06:00

Chimerix announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA(R) (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent BioSolutions, Inc. (Emergent). Additional closing conditions include the execution of an anticipated procurement contract between BARDA and Chimerix as well as receipt of any required consent from BARDA to a pre-novation agreement to be entered into with Emergent.

Neutral

Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement

2022-06-23 13:15:00

Chimerix announced a $9.3 million agreement to procure TEMBEXA(R) (brincidofovir) with a third party outside of North America, with authorization from the requisite healthcare authority. Chimerix expects to promptly provide treatment courses of TEMBEXA equivalent to the total value of the procurement contract. Execution of this contract will be the responsibility of Chimerix, as it is expected to occur prior to the close of the pending transaction with Emergent BioSolutions, Inc. (Emergent). In June 2022, Chimerix entered into a definitive agreement with Emergent to sell Chimerix's exclusive worldwide rights to brincidofovir including TEMBEXA, for up to $325 million plus royalties. Any revenue associated with TEMBEXA (brincidofovir) earned prior to closing of the Emergent transaction, and which is unrelated to the BARDA procurement contract (i.e., other U.S. revenue or international revenue), will accrue to Chimerix. For revenue earned after the close of the transaction, Chimerix will receive a 15% royalty on gross profit associated with international revenue and a 20% royalty on gross profit associated with U.S. revenue from sales in excess of 1.7 million treatment courses of therapy. There are several conditions required for the transaction with Emergent to close, including the expiration or early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act).

Negative

Chimerix, Inc.(NasdaqGM:CMRX) dropped from S&P Biotechnology Select Industry Index

2022-06-11 00:00:00

Chimerix, Inc.(NasdaqGM:CMRX) dropped from S&P Biotechnology Select Industry Index

Neutral

Chimerix, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 03:30 PM

2022-06-01 20:30:00

Chimerix, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 03:30 PM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Michael A. Sherman, CEO, President & Director.

Neutral

Chimerix, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM

2022-05-19 10:18:00

Chimerix, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States. Speakers: Michael A. Sherman, CEO, President & Director.

Positive

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

2022-05-16 00:00:00

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million on May 15, 2022. Under the terms of the agreement with Emergent, Chimerix will receive $225 million upon closing of the transaction plus up to $100 million in up to four $25 million milestone payments. Each milestone payment is contingent upon the exercise of future BARDA procurement options of TEMBEXA following the base period. The closing payment and the milestone payments may be adjusted based on actual procurement value. Chimerix is also eligible to receive up to $12.5 million in regulatory milestones associated with the SymBio Pharmaceuticals Ltd. brincidofovir partnership to be assumed by Emergent. Chimerix may also earn a 20% royalty on future gross profit of TEMBEXA in the United States associated with volumes above 1.7 million treatment courses of therapy during the exclusivity period of TEMBEXA. Outside of the United States, the agreement also allows Chimerix to earn a 15% royalty on all gross profit associated with TEMBEXA sales during the exclusivity period of TEMBEXA on a market-to-market basis. The transaction will be funded with Emergent's currently available funds. The transaction is subjected to the satisfaction or waiver of customary conditions, approval from BARDA and the expiration or early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act). The companies expect the transaction to close as early as the second quarter of 2022. Centerview Partners LLC acted as financial advisor and Jason Kent and Ian Nussbaum of Cooley LLP acted as legal counsel to Chimerix. Todd Overman and John Fuller of Bass, Berry & Sims PLC acted as legal counsel to Emergent BioSolutions.

Neutral

Maxim Group LLC, Exploring New Targets for Pediatric Brain Cancer, May 19, 2022

2022-05-12 20:15:00

Maxim Group LLC, Exploring New Targets for Pediatric Brain Cancer, May 19, 2022.

Neutral

Chimerix, Inc. Presents at Exploring New Targets for Pediatric Brain Cancer, May-19-2022 09:00 AM

2022-05-12 20:15:00

Chimerix, Inc. Presents at Exploring New Targets for Pediatric Brain Cancer, May-19-2022 09:00 AM. Speakers: Joshua E. Allen, Chief Technology Officer of Imipridones.

Neutral

Chimerix, Inc. to Report Q1, 2022 Results on May 16, 2022

2022-05-09 11:00:00

Chimerix, Inc. announced that they will report Q1, 2022 results on May 16, 2022

Neutral

Chimerix, Inc., Q1 2022 Earnings Call, May 16, 2022

2022-05-09 11:00:00

Chimerix, Inc., Q1 2022 Earnings Call, May 16, 2022

Neutral

Chimerix, Inc., Annual General Meeting, Jun 23, 2022

2022-04-28 17:08:00

Chimerix, Inc., Annual General Meeting, Jun 23, 2022, at 08:00 US Eastern Standard Time. Location: The Umstead Hotel and Spa, located at 100 Woodland Pond Drive, Cary Carey North Carolina United States Agenda: To consider election of the three class III directors; to ratification of the selection by the audit committee of the board of directors of Ernst & Young LLP as the independent registered public accounting firm of the company for fiscal year ending December 31, 2022; to approve, by non-binding vote, of the compensation of the company’s executive officers as disclosed in proxy statement; and to transact other matters.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Positive

Chimerix, Inc. Enters into Loan and Security Agreement

2022-02-01 11:14:00

On January 31, 2022, Chimerix, Inc. entered into a Loan and Security Agreement,by and between the Company, as borrower, and Silicon Valley Bank, as the lender. The Loan Agreement provides for a four-year secured revolving loan facility in an aggregate principal amount of up to $50.0 million. Proceeds from the Credit Facility may be used for working capital and general corporate purposes. The Company entered into the Loan Agreement to increase its financial flexibility by, among other things, providing a non-dilutive source of capital that can be drawn on to support its future working capital needs in light of the previously disclosed potential entry into a sole source contract with the Biomedical Advanced Research and Development Authority (BARDA"). The Company has no obligation to draw down any amount under the Credit Facility, and did not draw down any amount on the Effective Date. The Company views the Credit Facility as a resource that will supplement its financial position by providing an alternative source of capital that can be utilized on an as-needed basis, for example, in advance of an anticipated (or future) shipment of TEMBEXA treatment courses to BARDA into the U.S. Strategic National Stockpile over the term of the Credit Facility. The Company may borrow, repay and re-borrow funds under the Credit Facility without a prepayment penalty until January 31, 2026 (the Maturity Date"), at which time the Credit Facility expires, and all outstanding revolving loans under the Credit Facility, together with all accrued and unpaid interest, must be repaid. No exit fee exists upon expiration of the Credit Facility on the Maturity Date. Subject to the satisfaction of certain liquidity ratios, the full $50.0 million of the Credit Facility will be available for the Company to borrow on a non-formula basis. If the Company is unable to meet these liquidity ratios, then availability under the Credit Facility is determined based on a borrowing base equal to percentages of certain accounts receivable and certain purchase orders (which include prospective options for BARDA to procure TEMBEXA treatment courses) for the Company's goods in accordance with a formula set forth in the Loan Agreement. Borrowings under the Credit Facility accrue interest at a floating per annum rate of the greater of (i) 1.50% above the Prime Rate (as defined below) and (ii) 4.75%. Prime Rate is defined as the rate of interest per annum published in The Wall Street Journal or any successor publication thereto as the prime rate". If such rate of interest from The Wall Street Journal becomes unavailable, the Prime Rate" shall mean the rate of interest per annum announced by the Lender as its prime rate in effect. In each case, in the event such prime rate is less than zero, such rate shall be deemed to be zero for purposes of the Loan Agreement. The Company must also pay an unused line fee equal to 0.25% per annum on the unused portion of the Credit Facility, payable quarterly in arrears. Upon the termination of the Loan Agreement for any reason prior to the Maturity Date, the Company will be required to pay to the Lender an early termination fee of $0.5 million. The Loan Agreement also requires the Company to pay the Lender a non-refundable commitment fee of $0.5 million, payable in four equal installments beginning on the Effective Date and each anniversary of the Effective Date thereafter until January 31, 2025.

Neutral

Biomedical Advanced Research and Development Authority Issues Request for Proposal to Chimerix, Inc to Negotiate Sole Source Contract with the Company

2021-12-23 11:42:00

On December 22, 2021, the Biomedical Advanced Research and Development Authority issued a Request for Proposal to Chimerix, Inc. which confirmed, among other things, BARDA’s intent to negotiate a sole source contract with the Company for the development and procurement of a smallpox therapeutic with a mechanism of action distinct from that of TPOXX® (marketed by SIGA Technologies, Inc. (“SIGA”)) and with a New Drug Application accepted by the U.S. Food and Drug Administration (the “FDA”). The issuance of the RFP by BARDA is a requisite step in the sole source contracting process and allows the Company to commence negotiations with BARDA and to submit a proposal for a contract with BARDA. The RFP indicates that BARDA intends to contract with the Company to procure up to 1.7 million treatment courses of a smallpox antiviral. The RFP also requires the Company to perform certain activities to be supported by BARDA, including, but not limited to the execution of a randomized clinical trial in the event of an outbreak, and certain cGMP manufacturing activities. The final terms of any contract awarded under the RFP will be subject to future negotiations between BARDA and the Company, including, but not limited to, provisions concerning costs, fees, manufacturing schedules, timing of deliverables, duration and termination. The RFP requests any responsive proposals be submitted to BARDA no later than February 7, 2022 at 12 PM ET. The Company expects to submit a proposal for a sole source contract to BARDA prior to such submission deadline.

Positive

Chimerix, Inc.(NasdaqGM:CMRX) added to NASDAQ Biotechnology Index

2021-12-20 00:00:00

Chimerix, Inc. has been added to NASDAQ Biotechnology Index.

Positive

Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-Mutant Diffuse Midline Glioma to be Presented at the Society for Neuro-Oncology Annual Meeting

2021-11-19 12:00:00

Chimerix announced the presentation of positive data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mutant diffuse midline glioma. ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist for the treatment of recurrent gliomas that harbor the H3 K27M- mutation. These data will be presented by Isabel Arrillaga-Romany, MD, PhD, Director of Neuro-Oncology Clinical Trials, Massachusetts General Hospital Cancer Center tomorrow, November 20, 2021, during a plenary session at the Society for Neuro-Oncology (SNO) Annual Meeting in Boston, MA. In addition, Dr. Arrillaga-Romany will join management for a conference call on November 22, 2021 to give an additional overview of the data. ONC201 monotherapy exhibited durable and clinically meaningful efficacy in recurrent H3 K27M-mutant diffuse midline glioma (DMG) patients: Response Assessment in Neuro-Oncology Criteria for High Grade Gliomas (RANO-HGG) criteria assessed by dual reader blinded independent central review (BICR), Overall response rate (ORR): 20% (95% CI: 10 – 34%); including one complete response, Median duration of response (DOR): 11.2 months (95% CI: 3.8 – not reached), Median time to response: 8.3 months (range: 1.9 – 15.9), Disease control rate (DCR): 40% (95% CI: 26 – 55%), Progression-free survival (PFS): 35% (95% CI: 21 – 49%) at 6 months; 30% (95% CI: 17 – 44%) at 12 months, Response Assessment in Neuro-Oncology Criteria for Low Grade Gliomas (RANO-LGG) criteria assessed by dual reader BICR, ORR 26% (95% CI: 15 – 40%). Among evaluable patients (those receiving at least 4mg of dexamethasone daily at baseline), 46.7% achieved at least a 50% confirmed reduction in corticosteroid dose Among evaluable patients (those with a baseline performance status (KPS/LPS) score of 80 or lower), 20.6% achieved a confirmed improvement, indicative of improved quality of life. Overall survival 12 months: 57% (95% CI: 41 – 70%) and 24 months: 35% (95% CI: 21 – 49%). This cohort was comprised of the first 50 patients enrolled across five ONC201 clinical studies who met specific criteria based on feedback from the FDA. These patients were two years of age or older, had a measurable diffuse midline glioma with the H3 K27M- mutation, and had evidence of disease progression following prior therapy with at least radiation completed at least 90 days prior to enrollment. One serious adverse event was attributed by an investigator as possibly related to ONC201. Full safety data collection and analysis for this cohort is ongoing. Prior safety review of ONC201 identified the most commonly reported adverse events as nausea/vomiting, fatigue and decreased lymphocyte counts. The U.S. Food and Drug Administration (FDA) granted ONC201 Fast Track Designation for the treatment of adult recurrent H3 K27M-mutant HGG, Rare Pediatric Disease Designation for treatment of H3 K27M-mutant glioma, and Orphan Drug Designations for the treatment of glioblastoma and for the treatment of malignant glioma. Chimerix plans to meet with the FDA in 2022 following completion of ongoing chemistry, manufacturing and controls (CMC) clinical pharmacology studies and natural disease history evaluation.

Neutral

Chimerix, Inc. - Special Call

2021-11-19 12:00:00

To discuss presentation of positive data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mutant diffuse midline glioma

Neutral

Chimerix, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-12 13:09:00

Chimerix, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Positive

Chimerix to Seek Acquisition

2021-11-04 16:15:00

Chimerix, Inc. (NasdaqGM:CMRX) will look for acquisition. The company said, "In addition to our transactions with Cantex Pharmaceuticals, Inc. (Cantex), SymBio Pharmaceuticals Limited (SymBio) and Oncoceutics, Inc. (Oncoceutics), management is continuing to conduct a review and assessment of potential transaction opportunities with the goal of building our product candidate pipeline, including, but not limited to, licensing, merger or acquisition transactions, issuing or transferring shares of common stock, or the license, purchase or sale of specific assets, in addition to other potential actions aimed at maximizing stockholder value".

Positive

Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma

2021-11-04 11:00:00

Chimerix reported positive topline data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mutant glioma. ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist for the treatment of recurrent gliomas that harbor the H3 K27M mutation. An efficacy analysis by blinded independent central review (BICR) of the registration cohort determined the overall response rate (ORR) to be 20.0% (95% Confidence Interval (CI): 10.0-33.7%) as determined by Response Assessment in Neuro-Oncology Criteria for High Grade Gliomas (RANO-HGG). The median duration of response (mDOR) was 11.2 months (95% CI: 3.8 - not reached) and the median time to response (mTTR) was 8.3 months. The cohort for a potential registration of ONC201 was comprised of the first 50 patients enrolled across five ONC201 clinical studies who met certain criteria. These patients were two years of age or older, had measurable diffuse midline glioma, their tumor harbored the H3 K27M mutation and had evidence of disease progression following prior therapy with at least radiation completed at least 90 days prior to enrollment, among certain other criteria. The full BICR analysis will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting on November 20, 2021. The plenary presentation will include additional supporting evidence of disease control, clinical benefit, including neurological improvements as measured by performance status, reduction in the use of corticosteroids, and an analysis of overall survival. One serious adverse event was attributed by an investigator as possibly related to ONC201. Full safety data collection and analysis for this cohort is ongoing. Prior safety review of ONC201 identified the most commonly reported adverse events as nausea/vomiting, fatigue and decreased lymphocyte counts. The FDA granted ONC201 Fast Track Designation for the treatment of adult recurrent H3 K27M-mutant high-grade glioma, Rare Pediatric Disease Designation for treatment of H3 K27M-mutant glioma, and Orphan Drug Designations for the treatment of glioblastoma and for the treatment of malignant glioma.

Neutral

Chimerix, Inc. to Report Q3, 2021 Results on Nov 04, 2021

2021-10-28 11:00:00

Chimerix, Inc. announced that they will report Q3, 2021 results on Nov 04, 2021

Neutral

Chimerix, Inc., Q3 2021 Earnings Call, Nov 04, 2021

2021-10-28 11:00:00

Chimerix, Inc., Q3 2021 Earnings Call, Nov 04, 2021

Neutral

Chimerix, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 09:40 AM

2021-10-01 10:34:00

Chimerix, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 09:40 AM. Venue: Rancho Palos Verdes, California, United States. Speakers: Michael A. Sherman, CEO, President & Director.

Neutral

Chimerix, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-09 14:24:00

Chimerix, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Michael A. Sherman, CEO, President & Director, Michael T. Andriole, Chief Business Officer, Secretary & CFO.

Neutral

Chimerix, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-10-2021 10:55 AM

2021-08-02 10:14:00

Chimerix, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-10-2021 10:55 AM. Speakers: Michael A. Sherman, CEO, President & Director.

Neutral

Chimerix, Inc., Q2 2021 Earnings Call, Aug 05, 2021

2021-07-29 11:00:00

Chimerix, Inc., Q2 2021 Earnings Call, Aug 05, 2021

Neutral

Chimerix, Inc. to Report Q2, 2021 Results on Aug 05, 2021

2021-07-29 11:00:00

Chimerix, Inc. announced that they will report Q2, 2021 results on Aug 05, 2021

Neutral

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Fundamental Summary

At a high level, the metrics from Chimerix's Q1 financial report release were demonstrably negative. Their growth and value factors indicate a poor execution and strategy, which isn't generating exciting growth. These troubling results make a strong case for underperformance and for anticipating a significant downside. We therefore gave Chimerix a total score of 58 out of 100 and a UNDERPERFORM recommendation.

Chimerix reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported negative revenue was USD 0.084 million compared to revenue of USD 2.87 million a year ago. Net loss was USD 24.77 million compared to USD 97.42 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 1.21 a year ago. Diluted loss per share from continuing operations was USD 0.28 compared to USD 1.21 a year ago.

Business Description

Chimerix, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company’s approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix was incorporated in 2000 and is headquartered in Durham, North Carolina.

Sector Overview

Chimerix is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Chimerix's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 65.5 -34.8% 63
Liabilities 17.7 -45.1% 48
Price to Book 3.8 -54.0% 40
Cash & Equivalents 32.0 107.6% 95
Equity 47.8 -30.0% 46
EBITDA -99.8 -11.3% 50
Total Revenues 0.6 -71.8% 99
Parameter Value Change Score
Return on Equity -110.9 54.7% 62
Net Cashflow -0.1 99.6% 80
Capital Expenditure -0.1 36.2% 95
Asset Turnover 0.0 -76.7% 47
Free Cashflow -1.0 16.2% 84

* All values are TTM

The below chart reflects Chimerix's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Chimerix's peer average final assessment score stands on 63.0, Chimerix's score is 58.

  •  CMRX
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 6 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 7 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 8 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 9 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 10 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 11 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 12 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 13 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 14 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 15 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 16 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 17 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 18 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 19 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 20 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Chimerix's stock is now priced above its 5-day, but below its 50-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a positive setup in the near-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Chimerix's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 42.

Bearish 42
Close Price 2.04
52W Low 1.34
52W High 8.75
5D MA 1.93
50D MA 2.91
200D MA 5.08
MACD -0.23
RSI 2.94
STOCH 92.11

Balance Sheet Analysis

Chimerix's most recent balance sheet report was not encouraging. Chimerix publishes concerning book value factor metrics in this report. price to book ratio (P/B) now sits at 3.8 and represents -54.0% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. The company's book value factors were lackluster and showed that management hasn't figured out how to overperform expectations. Therefore, their book value factors earned a score of 40. Also, Chimerix published concerning equity metrics for this filing. In the current report, equity stood at 47.8, which represents a -30.0% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. Their equity metrics appear unremarkable relative to their peers. Consequently, their equity movement received a grade of 46. That said, one metric, Cash & Equivalents, stood out as strongly positive. Chimerix's management was effective in improving its cash and cash equivalents metrics, which now sit at 32.0. This represents 107.6% change from the last reporting period. This impressive growth, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Therefore, its cash and cash equivalents movement earned a score of 95. The company's balance sheet, Therefore, earned a score of 49.

Parameter Value Change Score
Assets 65.5 -34.8% 63
Liabilities 17.7 -45.1% 48
Price to Book 3.8 -54.0% 40
Cash & Equivalents 32.0 107.6% 95
Equity 47.8 -30.0% 46
* All values are TTM

The below chart describes Chimerix's performance as reflected on its balance sheet with respect to its peers. While Chimerix received a balance sheet score of 49, the average of its peers stands on 65.0.

  •  CMRX
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 6 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 7 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 8 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 9 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 10 1
CareDx, Inc 1.2B 54 67 52 39 51 52 11 1
MannKind Corporation 957.2M 79 59 50 40 64 57 12 1
Merus N.V. 941.6M 59 68 50 83 81 70 13 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 15 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 16 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 17 1
Affimed N.V. 415.0M 56 66 63 56 47 54 18 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 19 1
AC Immune SA 299.8M 84 64 47 53 75 68 20 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Overall, Chimerix's critical income statement metrics appear to signal strong support and a high likelihood of positive growth going forward. Chimerix reported highly encouraging numbers for its revenue efficiency. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. As a result, its revenue efficiency earned a score of 99. Also, In this filing, Chimerix reported a return on equity (ROE) ratio of -110.9, which represents a change of 54.7%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their return factors received a grade of 62. On the other hand, EBITDA, jumped out as looking problematic. Chimerix reported concerning EBITDA this period. At filing, EBITDA was reported as -99.8, representing -11.3% change from the previous period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. Their EBITDA metrics are even more problematic when compared to their peers. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 50. Consequently, their income statement earned a rank of 65.

Parameter Value Change Score
EBITDA -99.8 -11.3% 50
Total Revenues 0.6 -71.8% 99
Return on Equity -110.9 54.7% 62
* All values are TTM

The below chart describes Chimerix's performance as reflected on its income statement with respect to its peers. While Chimerix received a income statement score of 65 , the average of its peers stands on 67.0.

  •  CMRX
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Xencor, Inc. 1.6B 42 94 52 79 6 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 7 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 8 1
Veracyte, Inc. 1.4B 45 63 57 55 9 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 10 1
CareDx, Inc 1.2B 61 44 82 50 11 1
MannKind Corporation 957.2M 95 48 56 61 12 1
Merus N.V. 941.6M 48 60 59 54 13 1
Amarin Corporation plc 734.5M 95 44 82 63 14 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 15 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 16 1
Radius Health, Inc. 499.8M 94 71 68 82 17 1
Affimed N.V. 415.0M 95 49 75 66 18 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 19 1
AC Immune SA 299.8M 83 61 65 70 20 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Overall, Chimerix's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Chimerix's management was effective in improving its CapEx, which now sits at -0.1 and represents 36.2% change from the previous report. This performance is all the more impressive relative to their peers and competitors. The company's CapEx movement, therefore, received a grade of 95. Also, Chimerix's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. Chimerix recorded free cash flow of -1.0, which represents a 16.2% change from the previous report. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. Their free cash flow situation is all the more impressive relative to their peers and competitors. Consequently, their free cash flow movement received a grade of 84. At the same time, one critical cash flow metric, Asset Turnover, was notably weak. Asset turnover metrics during this period were surprisingly weak. Their reported asset turnover metrics of 0.0, which represents a -76.7% change from the previous report. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Their asset turnover numbers are significantly less impressive when compared to their peers and competitors. Correspondingly, their asset turnover movement received a grade of 47. Therefore, we scored their cash flow a 83.

Parameter Value Change Score
Net Cashflow -0.1 99.6% 80
Capital Expenditure -0.1 36.2% 95
Asset Turnover 0.0 -76.7% 47
Free Cashflow -1.0 16.2% 84
* All values are TTM

The below chart describes Chimerix's performance as reflected on its cash flow with respect to its peers. While Chimerix received a cash flow score of 83, the average of its peers stands on 67.0.

  •  CMRX
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Xencor, Inc. 1.6B 96 95 70 95 98 6 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 7 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 8 1
Veracyte, Inc. 1.4B 90 95 46 46 82 9 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 10 1
CareDx, Inc 1.2B 98 84 40 50 86 11 1
MannKind Corporation 957.2M 77 56 43 37 66 12 1
Merus N.V. 941.6M 70 71 74 53 71 13 1
Amarin Corporation plc 734.5M 52 40 74 55 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 15 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 16 1
Radius Health, Inc. 499.8M 64 40 37 56 57 17 1
Affimed N.V. 415.0M 72 57 95 43 74 18 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 19 1
AC Immune SA 299.8M 66 77 79 63 68 20 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.